|
1
|
Cronin KA, Lake AJ, Scott S, Sherman RL,
Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et
al: Annual report to the nation on the status of cancer, part I:
National cancer statistics. Cancer. 124:2785–2800. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yardley DA: Pharmacologic management of
bone-related complications and bone metastases in postmenopausal
women with hormone receptor-positive breast cancer. Breast Cancer
(Dove Med Press). 8:73–82. 2016.PubMed/NCBI
|
|
4
|
Futakuchi M and Singh RK: Animal model for
mammary tumor growth in the bone microenvironment. Breast Cancer.
20:195–203. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shioi Y, Kashiwaba M, Inaba T, Komatsu H,
Sugai T and Wakabayashi G: Long-term complete remission of
metastatic breast cancer, induced by a steroidal aromatase
inhibitor after failure of a non-steroidal aromatase inhibitor. Am
J Case Rep. 15:85–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fitzmaurice C, Dicker D, Pain A, Hamavid
H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R,
Wolfe C, et al Global burden of disease cancer collaboration, : The
global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang ML, Huang ZZ and Zheng Y: Estimates
and prediction on incidence, mortality and prevalence of breast
cancer in China, 2008. Zhonghua Liu Xing Bing Xue Za Zhi.
33:1049–1051. 2012.(In Chinese). PubMed/NCBI
|
|
10
|
Chen WQ and Zheng RS: Incidence, morality
and survival analysis of breast cancer in China. Chin J Clin Oncol.
42:668–674. 2015.(In Chinese).
|
|
11
|
He K, Li WX, Guan D, Gong M, Ye S, Fang Z,
Huang JF and Lu A: Regulatory network reconstruction of five
essential microRNAs for survival analysis in breast cancer by
integrating miRNA and mRNA expression datasets. Funct Integr
Genomics. 19:645–658. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
elife. 2015.4:e05005doi: 10.7554/eLife.05005. View Article : Google Scholar
|
|
14
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng X, Cao P, He D, Han S, Zhou J, Tan G,
Li W, Yu F, Yu J, Li Z and Cao K: MiR-634 sensitizes nasopharyngeal
carcinoma cells to paclitaxel and inhibits cell growth both in
vitro and in vivo. Int J Clin Exp Pathol. 7:6784–6791.
2014.PubMed/NCBI
|
|
18
|
Ye J, Zhang Z, Sun L, Fang Y, Xu X and
Zhou G: MiR-186 regulates chemo-sensitivity to paclitaxel via
targeting MAPT in non-small cell lung cancer (NSCLC). Mol Biosyst.
12:3417–3424. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duan L, Hao X, Liu Z, Zhang Y and Zhang G:
MiR-129-5p is down-regulated and involved in the growth, apoptosis
and migration of medullary thyroid carcinoma cells through
targeting RET. FEBS Lett. 588:1644–1651. 2016. View Article : Google Scholar
|
|
20
|
Jiang Z, Wang H, Li Y, Hou Z, Ma N, Chen
W, Zong Z and Chen S: MiR-129-5p is down-regulated and involved in
migration and invasion of gastric cancer cells by targeting
interleukin-8. Neoplasma. 63:673–680. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luan QX, Zhang BG, Li XJ and Guo MY:
MiR-129-5p is downregulated in breast cancer cells partly due to
promoter H3K27m3 modification and regulates epithelial-mesenchymal
transition and multi-drug resistance. Eur Rev Med Pharmacol Sci.
20:4257–4265. 2016.PubMed/NCBI
|
|
22
|
Luo H, Zhang H, Zhang Z, Zhang X, Ning B,
Guo J, Nie N, Liu B and Wu X: Down-regulated miR-9 and miR-433 in
human gastric carcinoma. J Exp Clin Cancer Res. 28:822009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X,
Zhou X and Gan J: A serum microRNA panel as potential biomarkers
for hepatocellular carcinoma related with hepatitis B virus. PLoS
One. 9:e1079862014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang T, Jiang K, Zhu X, Zhao G, Wu H,
Deng G and Qiu C: miR-433 inhibits breast cancer cell growth via
the MAPK signaling pathway by targeting Rap1a. Int J Biol Sci.
14:622–632. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meng R, Fang J, Yu Y, Hou LK, Chi JR, Chen
AX, Zhao Y and Cao XC: miR-129-5p suppresses breast cancer
proliferation by targeting CBX4. Neoplasma. 65:572–578. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zdenkowski N, Butow P, Tesson S and Boyle
F: A systematic review of decision aids for patients making a
decision about treatment for early breast cancer. Breast. 26:31–45.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu X, Zeng R, Wu S, Zhong J, Yang L and Xu
J: Comprehensive expression analysis of miRNA in breast cancer at
the miRNA and isomiR levels. Gene. 557:195–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
D'Angelo B, Benedetti E, Cimini A and
Giordano A: MicroRNAs: A puzzling tool in cancer diagnostics and
therapy. Anticancer Res. 36:5571–5575. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan JW, Lin JS and He XX: The emerging
role of miR-375 in cancer. Int J Cancer. 135:1011–1018. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Luan QX, Zhang BG, Li XJ and Guo MY:
MiR-129-5p is downregulated in breast cancer cells partly due to
promoter H3K27m3 modification and regulates epithelial-mesenchymal
transition and multi-drug resistance. Eur Rev Med Pharmacol Sci.
20:4,257–4,265. 2016.
|
|
31
|
Luo J, Chen J and He L: miR-129-5p
attenuates irradiation-induced autophagy and secreases
radioresistance of breast cancer cells by targeting HMGB1. Med Sci
Monit. 21:4122–4129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu K, Huang J, Ni J, Song D, Ding M, Wang
J, Huang X and Li W: MALAT1 promotes osteosarcoma development by
regulation of HMGB1 via miR-142-3p and miR-129-5p. Cell Cycle.
16:578–587. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo J, Chen J and He L: Mir-129-5p
attenuates irradiation-induced autophagy and decreases
radioresistance of breast cancer cells by targeting HMGB1. Med Sci
Monit. 21:4122–4129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gotanda K, Hirota T, Matsumoto N and Ieiri
I: MicroRNA-433 negatively regulates the expression of thymidylate
synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa
cells. BMC Cancer. 13:3692013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang K, Li L, Wu J, Qiu Q, Zhou F and Wu
H: The different expression profiles of microRNAs in elderly and
young human dental pulp and the role of miR-433 in human dental
pulp cells. Mech Ageing Dev. 146-148:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang T, Jiang K, Zhu X, Zhao G, Wu H,
Deng G and Qiu C: miR-433 inhibits breast cancer cell growth via
the MAPK signaling pathway by targeting Rap1a. Int J Biol Sci.
14:622–632. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen X, Ruan A, Wang X, Han W, Wang R, Lou
N, Ruan H, Qiu B, Yang H and Zhang X: miR-129-3p, as a diagnostic
and prognostic biomarker for renal cell carcinoma, attenuates cell
migration and invasion via downregulating multiple
metastasis-related genes. J Cancer Res Clin Oncol. 140:1295–1304.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zheng Q, Chen C, Guan H, Kang W and Yu C:
Prognostic role of microRNAs in human gastrointestinal cancer: A
systematic review and meta-analysis. Oncotarget. 8:46611–46623.
2017. View Article : Google Scholar : PubMed/NCBI
|
